Early-stage Nanotech Target a strategic partnership or licensing deal with Arytha Biosciences and Cellics Therapeutics to leverage their membrane-coating technology and nanoparticle expertise for co-development of oncology and biodetoxification programs.

Clinical Development Niche Pitch for supply, collaboration, or sponsored research in nanoparticle formulation and stability testing, leveraging Cello’s FDA-approved drug loading in polymer cores and RBC membrane coating to accelerate preclinical-to-clinical transitions.

Funding & Milestones Propose milestone-based grant or contract opportunities with biotech funders or CROs to support drug development, given the company’s current revenue has not scaled beyond a modest range and total funding stands at several million.

Low-Volume Ops Offer customized CRO/CMO services for small teams and early-stage programs, including nanoparticle synthesis, characterization, and in vivo planning, tailored to a 2-10 employee company with limited internal infrastructure.

Market Position Position as a specialized partner for oncology nanomedicine and pathogen detoxification initiatives, highlighting membrane-coated nanoparticle advantages to differentiate in collaborations with larger pharma players seeking novel delivery platforms.